Introduction {#S1}
============

Over the last three decades, survival of children with acute lymphoblastic leukaemia (ALL) has improved from around 50%[@R1] to nearer 80%.[@R2] During the same period the outcome for those who relapse has remained poor.[@R3]-[@R9] Relapses result when evolutionary pressures of frontline therapy favour emergence of a subclone from within the original blast population.[@R10] The incidence and pattern of relapses thus vary according to protocols used. Irrespective of frontline treatment, relapsed ALL is characterised by two recurring features. The first is the critical prognostic impact of the duration of first remission (CR1).[@R3],[@R7]-[@R9],[@R11] Patients who relapse within 18 months of initial diagnosis have a significantly worse outcome when compared to those with later relapses. The second is the predilection for relapse in extramedullary sites, particularly the central nervous system (CNS). At initial diagnosis, \<2% of children have disease within the CNS. This can rise to 40% at first relapse.[@R3],[@R7],[@R9] CNS relapses may occur isolated or in conjunction with marrow disease (combined relapse) - therapy outcomes appear to differ in these two groups. In a Children's Oncology Group (COG) report of standard risk ALL relapses, overall survival was better in children with isolated extramedullary rather than combined relapse.[@R8] The advent of sensitive molecular investigations has complicated the distinction between these two relapse categories. For instance, the Berlin-Frankfurt-Münster (BFM) group observed that \~80% of those with apparent isolated CNS relapse had molecular evidence of marrow disease. The numbers may be small and not adjusted for the duration of CR1 but the BFM observations also indicate a poorer outcome in extramedullary relapses with concomitant higher marrow tumour burden.[@R12]

We do not know why relapses occur in the CNS. Within the limitations of our understanding, modern ALL protocols are designed to limit CNS relapses. Over the last 3 decades in the UK and elsewhere, intrathecal chemotherapy has replaced cranial irradiation as CNS-directed prophylaxis for most children with ALL.[@R13] Along with progressive intensification of systemic therapy, these measures have in general been successful and the overall incidence of CNS relapses has steadily declined.[@R2] Nevertheless, CNS relapse remains a significant preventable and therapeutic challenge. What then has been the impact of modern therapies on the pattern of CNS relapses in childhood ALL? Have we reached the end of optimisation with conventional drugs or is there room for further refinement of existing therapy? To answer these questions we have analysed the trends in incidence and outcome of CNS relapses among children treated for ALL in the UK over a 17-year period spanning 4 trial eras. The 5-year event free survival (EFS) improved from around 60%[@R14] to nearly 80%[@R15] during this period.

Patients and Methods {#S2}
====================

Patients {#S3}
--------

All patients, treated on national protocols for childhood ALL between 1985 and 2001 and who experienced a relapse in the CNS, were included in these analyses. Patients with a non-CNS relapse (n-CNSr) were included for comparison. For purposes of this study, an isolated CNS relapse (i-CNSr) was defined as the presence of ≥5 white blood cells (WBC) per μl in cerebrospinal fluid with blasts identified on cytospin, or a biopsy-proven recurrence in the CNS or eye, in the absence of morphological disease in the bone marrow. A combined relapse (c-CNSr) was defined as the presence of CNS disease with ≥5% blasts in the bone marrow aspirate. Patients aged 1--9·99 years at presentation with diagnostic WBC counts \<50×10^9^/L were designated NCI (National Cancer Institute) Standard Risk; all other patients were classified as NCI High Risk. Relapses were categorised as very early, early or late based on time to relapse from first diagnosis, i.e. \<18 months, 18--30 months or ≥30 months respectively.

Clinical Trials {#S4}
---------------

The Medical Research Council (MRC) clinical trials that ran during this period have previously been reported and include chronologically, UKALLX,[@R16] UKALLXI,[@R17],[@R18] and ALL97.[@R15],[@R19] A major amendment was made to ALL97 in 1999 and the second phase of this trial is analysed separately (ALL97/99).[@R20] Salient relevant differences between the trials are outlined in [Table 1](#T1){ref-type="table"} and in the Supplemental. For purposes of analyses, patients have been grouped according to category of relapse (i-CNSr, c-CNSr or n-CNSr), NCI risk group, time to relapse and immunophenotype.[@R7] Analyses were censored to the annual follow-up of 30^th^ April 2007 for UKALLX and UKALLXI and to 31^st^ October 2007 for ALL97 and ALL97/99. The small numbers of patients lost to follow-up were censored at the date of last contact. Median follow-up from commencement of treatment for UKALLX is 18·6 (range 0·0--22·3) years, for UKALLXI is 13·0 (range 0·3--16·6) years, for ALL97 is 9·3 (range 3·5--10·8) years and for ALL97/99 is 6·6 (range 2·3--8·0) years.

Cytogenetic and molecular genetic characterisation {#S5}
--------------------------------------------------

Diagnostic cytogenetics was performed at regional laboratories and karyotypes were confirmed centrally.[@R21] Some UKALLXI patients treated after 1994 were screened for *ETV6-RUNX1* fusion using reverse transcriptase polymerase chain reaction.[@R18] Fluorescent *in situ* hybridization (FISH) analyses for *ETV6-RUNX1* and other translocations became routine from the start of ALL97. High hyperdiploidy (HH) was characterised by karyotyping (51--65 chromosomes) or by centromere FISH (using the Multiprobe-I system or by detection of classic trisomies).[@R22] Patients were classified as having an *MLL* rearrangement if an established 11q23/*MLL* translocation was seen on karyotyping or if a split signal pattern was observed using a breakapart *MLL* FISH probe.

Statistical Methods {#S6}
-------------------

Analyses of relapse excluded patients who died without attaining remission. Differences in clinical features, cytogenetics and proportions of relapses between patients enrolled on the distinct protocols were analysed by the chi-squared test. The long follow-up means that analyses using simple proportions are equivalent to competing risk cumulative incidence calculations. These proportions indicate the number of patients experiencing an event of interest given the level of competing events and, when added for the different relapse categories, provide the total relapse rate. Kaplan-Meier life tables were constructed for survival curves and trials were compared using the log-rank test. Patients were censored at events other than the one of interest. Secondary malignant neoplasms (SMNs) were included in EFS estimations ([Table 1](#T1){ref-type="table"}) and all post-SMN ALL relapses (overall, 3) were included in the analyses. Overall survival (OS) post relapse was defined as the time between first relapse and death from any cause. Univariate analyses using log-rank tests were performed to examine the significance of a number of variables in relation to risk of relapse and overall survival. Multivariate Cox regression analysis was used to determine factors independently associated with outcome. Both methods of analysis (proportions and Kaplan-Meier) provide different information and both have thus been presented.[@R23] All p-values quoted are two-sided. Analyses were carried out using SAS statistical software, version 9·1 (SAS Institute Inc, Cary, NC, USA), and in-house programs.

Results {#S7}
=======

A total of 5637 children with ALL were enrolled in MRC clinical trials in childhood ALL throughout this 17-year period (1985--2001). 73 (1·3%) failed to achieve remission and are excluded from further analyses ([Table 1](#T1){ref-type="table"}). Of the 5564 evaluable patients, 1748 (31%) experienced relapse of whom 1168 (67%) were n-CNSr, 273 (16%) were c-CNSr and 307 (18%) were i-CNSr ([Table 2](#T2){ref-type="table"}). 93 (1·7%) had CNS disease at original diagnosis, of whom 27 subsequently relapsed.

Change in incidence and pattern of CNS relapses with protocols {#S8}
--------------------------------------------------------------

During this period, both EFS and OS have improved with significant declines in both CNS and non-CNS relapses ([Figure 1A-C](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Among those who relapsed in the CNS, the proportion with c-CNSr has fallen (p = 0·0001) while the proportion of i-CNSr has remained relatively unchanged (p = 0·8) ([Table 2](#T2){ref-type="table"}).

Change in time to CNS relapse with protocols {#S9}
--------------------------------------------

Along with the decrease in relapse rates, the duration of CR1 prior to relapse has also changed ([Table 3](#T3){ref-type="table"}). As the lowest relapse rates were seen with ALL97/99, a comparison has been made between ALL97/99 and all previous trials. Among relapsing patients, while the proportion of very early relapses is similar for pre-ALL97/99 and ALL97/99, there has been a drop in the proportion of early relapses, and an increase in late relapses (p\<0·0001). This change in the timing of relapse with trials is also seen in c-CNSr (p=0·01) and n-CNSr (p=0·0004), but not in i-CNSr (p=0·5).

Factors influencing risk of CNS relapse {#S10}
---------------------------------------

[Table 4](#T4){ref-type="table"} shows the influence of risk factors on recurrence. Age, WBC count and NCI risk group were significant risk factors across all relapse categories. Unlike n-CNSr, gender was not a risk factor for CNS relapse. Immunophenotype influenced i-CNSr and n-CNSr but not c-CNSr. When analysed by trial, there were no differences in the effect of risk factors, with two exceptions (data not shown). First, the effect of gender on n-CNSr differed significantly by trial protocol (p(heterogeneity)=0·0001), with the greatest effect seen in the earlier trials. Second, while there was a suggestion that the effect of the T-cell immunophenotype on i-CNSr differed with trial (p(heterogeneity)=0·02), this was no longer observed when the less-than-robust data from UKALLX was excluded from the analyses (p=0·6).

We have sufficient data to analyse the pattern of relapses in the four main cytogenetic subtypes ([Table 5](#T5){ref-type="table"}). There was a significant decrease in relapse rates in *ETV6-RUNX1* patients over successive protocols (p\<0·0001). The change in pattern was similar to that observed for the whole group, i.e. a proportionate decrease in c-CNSr but not in i-CNSr with time. Patients with HH ALL also showed a significant decline in relapse rates (p\<0·0001), primarily between UKALLXI and ALL97. Unlike in *ETV6-RUNX1* patients, there was no apparent change in relapse pattern, with the proportion of i-CNSr and c-CNSr remaining essentially unchanged over the trials ([Table 5](#T5){ref-type="table"}). Although numbers were small, there were also suggestions of a decrease in relapse rates over time in those with *MLL* (p(trend)=0·009) and t(9;22) (p(trend)=0·05) rearrangements. A decline in i-CNSr was seen in t(9:22) disease, with none observed in the later trials. However increasingly with trials, patients with adverse cytogenetic subtypes received an allograft in CR1 and thus in ALL97 and ALL97/99 most patients with t(9;22) and *MLL* rearrangements would have been transplanted.[@R24]

Outcome following CNS relapse {#S11}
-----------------------------

Similar to the COG experience,[@R8] the overall outcome was significantly better in patients with i-CNSr (p=0·04)(Supplemental). Supplementary Figure S1[A](#SD4){ref-type="supplementary-material"}-[C](#SD6){ref-type="supplementary-material"} shows differences in post-relapse OS in each relapse category by trial. There were excess relapses in UKALLXI ([Table 2](#T2){ref-type="table"}) but many patients were subsequently salvaged. Excluding UKALLXI, there is no significant difference in post-relapse OS for UKALLX, ALL97 and ALL97/99. The 5-year OS post c-CNSr in UKALLX and ALL97/99 are comparable. While OS post n-CNSr appeared to be better, and for i-CNSr worse in ALL97/99, when compared to UKALLX these differences are not statistically significant.

The prognostic significance of a number of variables in relation to outcome post relapse is shown in [Table 6](#T6){ref-type="table"}. Univariate analyses showed that time to relapse, WBC count, adverse cytogenetics and NCI risk group were predictive of OS for all categories of relapse. As with n-CNSr, age and HH were predictive for OS in i-CNSr while immunophenotype and the *ETV6-RUNX1* genotype significantly influenced post-relapse OS in c-CNSr. Multivariate analysis, after exclusion of cytogenetic subtypes due to small numbers and missing data, confirmed the independent prognostic impact of time to relapse on post-relapse OS in all three relapse categories. Additional factors independently and significantly associated with post-relapse OS were WBC count (i-CNSr and n-CNSr) and the blast immunophenotype (c-CNSr and n-CNSr).

Besides time to relapse, multivariate analysis indicated that the trial period significantly influenced post-relapse OS across all relapse categories. The choice of steroid in frontline therapy has been reported to influence outcome.[@R15] Overall, EFS was significantly higher with frontline dexamethasone treatment ([Table 1](#T1){ref-type="table"}), although within trials, this effect was observed in ALL97 and not in ALL97/99. However, frontline steroid therapy had no significant influence on OS in relapsed patients who were randomised to receive either prednisolone 40mg/m^2^ (n=280) or dexamethasone 6·5mg/m^2^ (n=120) in frontline protocols (p=0·4). This was equally true for post-relapse OS in each relapse category \[p(heterogeneity)=0·2)\] although numbers in these subgroups were small.

Transplantation {#S12}
---------------

The proportion of patients treated with an allogeneic stem cell transplant (SCT) has decreased progressively with each trial (p\<0·0001) as has the proportion of transplants carried out post relapse over time, p(trend)=0·0007 ([Supplementary Table S1](#SD3){ref-type="supplementary-material"}). There was no significant variation in the proportion of patients receiving a transplant post i-CNSr or n-CNSr over the study period. There was a decrease in SCT for those with c-CNSr (p=0·02), although numbers are small for ALL97/99. In patients transplanted post CNS relapse (i-CNSr or c-CNSr), two-year OS, defined from the date of transplant, was 46% (95% CI: 34%--58%) in UKALLX, 64% (56%--72%) in UKALLXI, 55% (40%--70%) in ALL97 and 65% (40%--90%) in ALL97/99. Comparison of outcome between patients treated with chemotherapy only and those treated with SCT has not been attempted due to the inherent bias in therapy selection.

Discussion {#S13}
==========

Our analyses confirm that current UK therapy for ALL is effective in preventing extramedullary relapses in most children. This does not adequately explain why the decline in CNS relapses is seen predominantly in combined relapses or the proportionately little change in the pattern of i-CNSr with progressive trials.

Though UKALLXI investigated different CNS-directed therapies, the highest incidence of all relapses, and notably c-CNSr, were seen during this era. In UKALLX all children received cranial irradiation and an anthracycline during induction.[@R16] In ALL97/99, anthracyclines were only given to NCI high risk patients or those with poor early response to therapy[@R15],[@R20] and radiotherapy was reserved for those with CNS disease at diagnosis. Nevertheless there is a significant decrease in relapse rates in all categories in ALL97/99. Thus CNS recurrence can largely be prevented without the use of high dose methotrexate or cranial irradiation. The more frequent use of intrathecal methotrexate is contributory, but as this was introduced in UKALLXI, it is not the sole factor. In ALL97 and ALL97/99, steroid therapy was randomised between prednisolone and dexamethasone. The latter is thought to have better penetration into the CNS. While significant improvements in EFS and in both CNS and non-CNS relapse rates were seen with dexamethasone, there was no difference in OS.[@R15] Additionally, there was no significant heterogeneity of effect of the randomised steroid on outcome by trial. Thus other chemotherapeutic changes in ALL97/99 are primarily responsible for the improvement in outcome between ALL97 and ALL97/99. In ALL97/99, UKALLX/ALL97 intensification phases were replaced with BFM-type consolidation blocks, therapy was risk stratified and intrathecal therapy extended. The duration of therapy for boys was extended to 3 years, so that from 1998, most boys received 3 instead of 2 years of therapy. The additional randomisation of 6-mercaptopurine with 6-thioguanine (6-TG) found the latter to be protective against i-CNSr, but also hepatotoxic.[@R19] Although synergy with dexamethasone is a possibility, neither 6-TG nor its active metabolites cross the blood brain barrier.[@R19] Thus the evidence suggests that risk-stratified intensification of systemic therapy along with frequent intrathecal chemotherapy is the most successful approach to prevention of CNS relapse. A similar observation has been reported by COG in the CCG-1961 study. Children receiving early post induction intensification of therapy showed a significant decrease in n-CNSr and c-CNSr but not i-CNSr.[@R25]

Thus both intensification and more frequent intrathecal therapy appear to have played a role in the decline in CNS relapses. With multi-agent chemotherapy, it is difficult to identify the key responsible agent(s). The differential relapse trends in the cytogenetic subtypes offer room for speculation. In patients with *ETV6-RUNX1*, the incidence of relapses has progressively decreased with each successive protocol from UKALLXI onwards. Further decline in *ETV6-RUNX1* associated relapses in ALL97/99 occurs primarily in the c-CNSr group. We have already commented on the fact that the improvement in outcome with ALL97/99 cannot be attributed to dexamethasone alone. *ETV6-RUNX1* leukaemias are thought to benefit from intensive asparaginase therapy.[@R26],[@R27] UKALLXI and ALL97 used suboptimal doses of Erwinase. The improved outcome of *ETV6-RUNX1* patients in ALL97/99 is probably related to the more effective use of *E. coli* asparaginase (Elspar®, Merck, USA) in this trial. The additional intensification of asparaginase therapy in ALL2003 is expected to further reduce *ETV6-RUNX1* relapses. In HH ALL, a predilection for extramedullary relapses in patients treated on contemporary chemotherapy regimens has been reported from a single centre.[@R28] Though relapses in HH patients halved in ALL97, ALL97/99 provided no apparent further benefit and overall, the proportion of i-CNSr and c-CNSr has remained the same over trials. HH ALLs are more likely to be responsive to intensive methotrexate regimens.[@R28] In UKALLXI, high dose intravenous methotrexate (HDMTX) was found to be protective against i-CNSr.[@R13] The relapse rate for HH is also lower in this protocol than that for *ETV6-RUNX1*. It is thus tempting to postulate that outcome in patients with HH may be further improved by the targeted reintroduction of HDMTX in future trials. Thus, there are still opportunities to biologically adapt current therapy to improve outcomes.

Though the incidence of relapse has decreased with time, post-relapse outcomes have not improved. This suggests that by optimising treatment, we are now preventing relapses in those who were earlier cured with salvage therapy. Given our incomplete understanding of why CNS relapses occur and the paucity of new agents, the best therapeutic strategy remains unclear. The results of transplantation in children with i-CNSr relapses have been variable.[@R7],[@R8],[@R11],[@R30]-[@R32] In retrospect, a number of children who were transplanted for disease recurrence in earlier trials would have been cured by current chemotherapy. The standard approach for those who are not transplanted is chemoradiotherapy. However, there is little consensus on the dose, type and timing of CNS irradiation.[@R2] Radiotherapy no longer has a role in preventing CNS relapses in frontline therapy. Is it really of benefit as a therapeutic adjunct to systemic chemotherapy in relapsed disease? This is a difficult question to answer as the small numbers and heterogeneity of disease preclude a randomised approach to this problem. At the moment the most effective strategy remains prevention of disease recurrence. Our analyses suggest that both the biological heterogeneity of the disease and combined systemic and intrathecal chemotherapy influence the incidence and pattern of CNS relapse. Thus further optimisation with currently available agents is possible and may further decrease CNS recurrence.

Supplementary Material {#SM}
======================

Supplementary Information accompanies the paper on the Leukemia website (<http://www.nature.com/leu>).
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###### 

Kaplan-Meier analysis of cumulative incidence of site-specific relapse censored for death in remission or alternative site of relapse. (A) i-CNSr (B) c-CNSr and (C) n-CNSr. p-values are for heterogeneity between trials.
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###### 

Details of MRC childhood ALL trials analysed in this study. Both five-year EFS and OS have improved with trials. The proportion of boys and girls, immunophenotype, CNS disease at diagnosis and NCI risk groups are comparable between trials. The age limit of eligibility increased from ALL97 onwards and as a result, a greater proportion of older children and slightly fewer younger children were recruited to ALL97 and ALL97/99 when compared with previous trials

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                               UKALLX                 UKALLXI               ALL97                          ALL97/99
  ----------------------------------------------------------------------------------------- -------------------------------------------------- ---------------------- --------------------- ------------------------------ -------------------------
  Time period                                                                                                                                  1985--1990             1991--1997            1997--1999                     1999--2001

  Number enrolled                                                                                                                              1612                   2090                  997 (151 on HR1)               938

  Number achieving CR1 (%)                                                                  1573 (97·6%)                                       2076 (99·3%)           983 (98·6%)           932 (99·4%)                    

  [\*](#TFN1){ref-type="table-fn"}Survival rates (95% CI)                                   5 year EFS (%)                                     61·9                   62·8                  73·8                           79·8

                                                                                                                                               (59·5--64·3)           (60·6--65·0)          (71·1--76·5)                   (77·3--82·3)

                                                                                            5 year OS (%)                                      77·4                   84·6                  83·5                           88·0

                                                                                                                                               (75·8--79.0)           (83·3--85·9)          (81·5--85·5)                   (86·2--89·8)

  Age Eligibility (yrs)                                                                                                                        0--14                  1--14                 1--17                          1--17

  Age at diagnosis (yrs)                                                                    \<2                                                163 (10%)              157 (8%)              76 (8%)                        63 (7%)

                                                                                            2--9                                               1212 (75%)             1617 (77%)            716 (72%)                      680 (72%)

                                                                                            ≥10                                                237 (15%)              316 (15%)             205 (20%)                      195 (21%)

  WBC                                                                                       \<50 × 10^9^/l                                     1270 (79%)             1628 (78%)            770 (77%)                      717 (76%)

                                                                                            ≥50 × 10^9^/l                                      342 (21%)              462 (22%)             227 (23%)                      221 (24%)

  Immunophenotype                                                                           Non T-cell                                         1397 (86%)             1730 (83%)            863 (86%)                      831 (88%)

                                                                                            T-cell                                             139 (9%)               206 (10%)             118 (12%)                      92 (10%)

                                                                                            Unknown                                            76 (5%)                154 (7%)              16 (2%)                        15 (2%)

  CNS disease at diagnosis                                                                  No                                                 1583 (98·2%)           2059 (98·5%)          979 (98·2%)                    918 (97·9%)

                                                                                            Yes                                                29 (1·8%)              31 (1·5%)             18 (1·8%)                      20 (2·1%)

  [‡](#TFN2){ref-type="table-fn"}Induction                                                  Anthracycline                                      Yes                    None post 1992        No                             For IR and HR

                                                                                            Steroid                                            Prednisolone           Prednisolone          Randomised                     Randomised

  Intensification                                                                           Intensification\                                   Randomised, none, 1\   Randomised 2 or 3\    Randomised 2 or 3 blocks       2 BFM type delayed\
                                                                                            blocks                                             or 2 short blocks      blocks                                               intensification blocks

  Duration of treatment                                                                                                                        2 years                2 years               2 years\                       Girls: 2 years\
                                                                                                                                                                                            For boys, 3 years after 1998   Boys: 3 years

  [†](#TFN3){ref-type="table-fn"}CNS directed therapy                                       Randomised                                         No                     Yes                   No                             No

                                                                                            Cranial irradiation                                18 Gy for all          WBC ≥50×10^9^/L:      Initially as UKALL XI          Only for CNS disease

                                                                                                                                                                      24 Gy or HD MTX       (XRT = 39) and later           

                                                                                                                                                                      WBC \<50×10^9^/L:     only for CNS disease           

                                                                                                                                                                      HD MTX or IT MTX                                     

                                                                                            IV MTX                                             No                     HD MTX                No                             Capizzi for HR patients

                                                                                            Continuing IT\                                     No                     For those without\    Yes                            Yes
                                                                                            MTX                                                                       cranial irradiation                                  

  Deaths in CR1                                                                             71 (4·5%)                                          42 (2·0%)              34 (3·4%)             36 (3·9%)                      

  Second Malignant Neoplasms (Deaths)                                                       30 (18)                                            16 (12)                6 (2)                 5 (2)                          

  Number of patients treated with different CNS-directed therapies in UKALL XI and ALL 97                                                                                                                                  

  WBC ≥50 × 10^9^/l\                                                                        XRT                                                                       133                   39                             
  treatment received                                                                                                                                                                                                       

  HDMTX + ITMTX                                                                                                                                160                    93                                                   

                                                                                            Unknown                                                                   17                    3                              

                                                                                            [\*\*](#TFN4){ref-type="table-fn"}Very high risk                          152                   92                             

  WBC ≥50 × 10^9^/l\                                                                        XRT                                                                       186                                                  
  randomised                                                                                                                                                                                                               

  HDMTX + ITMTX                                                                                                                                188                                                                         

  WBC \<50 × 10^9^/l\                                                                       HDMTX + ITMTX                                                             754                                                  
  randomised                                                                                                                                                                                                               

  ITMTX                                                                                                                                        759                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CR1 = first complete remission

CI = confidence intervals; EFS = Event Free Survival; OS = Overall Survival. Deaths in CR1 include deaths from second malignant neoplasms.

For ALL97/99, IR = Intermediate Risk, children aged ≥10 years or with a presenting WBC of ≥50 × 10^9^/l; HR = High Risk, adverse cytogenetics \[(t(9;22), *MLL* rearrangements near-haploid or hypodiploid karyotype\] or slow early response to therapy. Steroid randomisation was dexamethasone (6·5 mg/m^2^) or prednisolone (40 mg/m^2^).

HD MTX = High dose intravenous methotrexate, 6--8 gm/m^2^; ITMTX = intrathecal methotrexate. Capizzi = escalating doses of intravenous methotrexate with timed L-Asparaginase during interim maintenance, XRT = Cranial irradiation.

Very high risk based on the Oxford hazard score[@R33] or cytogenetics. In UKALLXI very high risk patients were recommended transplant and hence received total body irradiation rather than XRT or HDM. In ALL97, very high risk patients were treated on HR1.

###### 

Number of relapses in each relapse category by trial. i-CNSr = isolated CNS relapse, c-CNSr = combined CNS relapse, n-CNSr = non-CNS relapse. Numbers in brackets represent proportions (equivalent to competing risk cumulative incidence) within each relapse category for all patients (top) and for all relapses *\[bottom in italics\]*. p-values are for heterogeneity between trials

  -------------------------------------------------------------------------------------------------------------------------------------------------
                 UKALLX (n=1573)   UKALLXI (n=2076)   ALL97 (n=983)   ALL97/99 (n=932)   p value\                                        
                                                                                         (heterogeneity)                                 
  -------------- ----------------- ------------------ --------------- ------------------ ----------------- ----------- ----- ----------- ----------
  All relapses   558               (35%)              790             (38%)              238               (24%)       162   (17%)       \<0·0001

  i-CNSr         104               (7%)               132             (6%)               44                (5%)        27    (3%)        0·0001

                                   *\[19%\]*                          *\[17%\]*                            *\[18%\]*         *\[17%\]*   0·8

  c-CNSr         67                (4%)               150             (7%)               43                (4%)        13    (1%)        \<0·0001

                                   *\[12%\]*                          *\[19%\]*                            *\[18%\]*         *\[8%\]*    0·0001

  n-CNSr         387               (25%)              508             (24%)              151               (15%)       122   (13%)       \<0·0001

                                   *\[69%\]*                          *\[64%\]*                            *\[63%\]*         *\[75%\]*   0·02
  -------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Changing trends in time to relapse from first diagnosis in children treated on MRC ALL protocols. A comparison is made between ALL97/99 and all other trials. Compared to earlier trials, c-CNSr and n-CNSr occur later in ALL97/99. The proportion and timing of i-CNSr remains unchanged. Numbers in brackets are percentages of total relapses in each category. p-values for heterogeneity between trials correspond to comparison of pre-ALL97/99 trials with ALL97/99

                           UKALLX    UKALLXI   ALL97     pre-ALL97/99   ALL97/99   p-value           
  ------------------------ --------- --------- --------- -------------- ---------- --------- ------- ----------
  **Any relapse**                                                                                    
  Very Early (\<18 mths)   139       148       71        358            (23%)      42        (26%)   \<0·0001
  Early (18--30 mths)      183       278       55        516            (33%)      25        (15%)   
  Late (≥30 mths)          236       364       112       712            (45%)      95        (59%)   
  **Total**                **558**   **790**   **238**   **1586**                  **162**           
  **i-CNSr**                                                                                         
  Very Early (\<18 mths)   42        57        19        118            (42%)      10        (37%)   0·5
  Early (18--30 mths)      48        58        17        123            (44%)      11        (41%)   
  Late (≥30 mths)          14        17        8         39             (14%)      6         (22%)   
  **Total**                **104**   **132**   **44**    **280**                   **27**            
  **c-CNSr**                                                                                         
  Very Early (\<18 mths)   13        18        1         32             (12%)      4         (31%)   0·01
  Early (18--30 mths)      26        59        15        100            (38%)      0         (0%)    
  Late (≥30 mths)          28        73        27        128            (49%)      9         (69%)   
  **Total**                **67**    **150**   **43**    **260**                   **13**            
  **n-CNSr**                                                                                         
  Very Early (\<18 mths)   84        73        51        208            (20%)      28        (23%)   0·0004
  Early (18--30 mths)      109       161       23        293            (28%)      14        (11%)   
  Late (≥30 mths)          194       274       77        545            (52%)      80        (66%)   
  **Total**                **387**   **508**   **151**   **1046**                  **122**           

###### 

Log-rank analyses of variables influencing recurrence in each relapse category. O/E = Observed/Expected ratio

  -----------------------------------------------------------------------------------------------------------------------------------------
  Variable                       No.\       i-CNSr                          c-CNSr                       n-CNSr         
                                 patients                                                                               
  ----------------- ------------ ---------- -------- ----- ---------------- -------- ----- ------------- -------- ----- -------------------
  Sex               Male         3166       180      1·1   0·3              166      1·1   0·05          786      1·2   \<0·0005

                    Female       2398       127      0·9                    107      0·9                 382      0·7   

  WBC (× 10^9^/L)   \<50         4340       188      0·8   \<0·00005        194      0·9   \<0·00005     865      0·9   \<0·0005

                    ≥50          1224       119      2·1                    79       1·7                 303      1·5   

  Age (years)       \<2          452        53       2·2   \<0·00005        30       1·4   0·04          68       0·7   \<0·00005

                    2--9         4178       208      0·9   0·0006 (trend)   198      0·9   0·8 (trend)   828      0·9   \<0·00005 (trend)

                    10+          934        46       1·0                    45       1·2                 272      1·6   

  NCI risk          Standard     3655       165      0·8   \<0·00005        162      0·8   \<0·00005     665      0·8   \<0·00005

                    High         1909       142      1·5                    111      1·4                 503      1·5   

  Immunophenotype   non T-cell   4767       257      1·0   0·02             241      1·0   0·4           961      1·0   \<0·00005

                    T-cell       539        35       1·5                    25       1·2                 138      1·6   
  -----------------------------------------------------------------------------------------------------------------------------------------

###### 

Changing trends in relapses in four cytogenetic subtypes over successive trials. The rise in incidence of translocation-associated leukaemias in the later trials reflects the use of FISH screening. The proportion of children in each cytogenetic group does not differ by trial, with the exception of *MLL* rearrangements (infants included in UKALLX but not in UKALLXI). The numbers screened represent the number of patients in each trial with available cytogenetic data. Numbers in brackets represent percentages of total relapses in each group

  --------------------------------------------------------------------------------------
                         UKALLX      UKALLXI     ALL97       ALL97/99    p-value
  ---------------------- ----------- ----------- ----------- ----------- ---------------
  ***ETV6-RUNX1***                                                       

  Screened               No Data     663         764         869         

  N (% of screened)      131 (20%)   175 (23%)   194 (22%)   0·3         

  *Relapses*                         37%         17%         9%          \<0·0001\
                                                                         (trend\
                                                                         \<0·0001)

  i-CNSr                             6 (19%)     3 (10%)     4 (24%)     0·1

  c-CNSr                             9 (12%)     9 (30%)     0           

  n-CNSr                             33 (69%)    18 (60%)    13 (76%)    

  **HH**                                                                 

  Screened               547         1656        862         792         

  N (% of screened)      197 (36%)   528 (32%)   294 (34%)   272 (34%)   0·3

  *Relapses*             27%         30%         16%         15%         \<0·0001\
                                                                         (trend\
                                                                         \<0·0001)

  i-CNSr                 13 (24%)    26 (16%)    9 (20%)     8 (20%)     0·6

  c-CNSr                 6 (11%)     31 (20%)    8 (17%)     4 (10%)     

  n-CNSr                 35 (65%)    103 (64%)   29 (63%)    28 (70%)    

  **t(9;22)**                                                            

  Screened               547         1656        931         903         

  N (% of screened)      11 (2%)     26 (2%)     17 (2%)     26 (3%)     0·2

  *Relapses*             64%         58%         53%         35%         0·3\
                                                                         (trend 0·05)

  i-CNSr                 3 (43%)     2 (13%)     0           0           0·1

  c-CNSr                 0           1 (7%)      1 (11%)     0           

  n-CNSr                 4 (57%)     12 (80%)    8 (89%)     9 (100%)    

  ***MLL* rearranged**                                                   

  Screened               547         1660        932         901         

  N (% of screened)      15 (3%)     23 (1%)     14 (2%)     24 (3%)     0·04

  *Relapses*             60%         65%         50%         25%         0·03\
                                                                         (trend 0·009)

  i-CNSr                 2 (22%)     0           0           2 (33%)     0·2

  c-CNSr                 0           3 (20%)     2 (29%)     1 (17%)     

  n-CNSr                 7 (78%)     12 (80%)    5 (71%)     3 (50%)     
  --------------------------------------------------------------------------------------

###### 

Log-rank analyses of factors influencing outcome in each category of relapse (incomplete data for cytogenetic subtypes). O/E = Observed/Expected ratio

  Variable                         Post i-CNSr               Post c-CNSr                Post n-CNSr                                   
  ------------------ ------------- ------------- ----- ----- -------------- ----- ----- ------------- ------------- ----- ----- ----- -------------------
  Sex                Male          180           102   1·0   0·7            166   97    1·1           0·2           786   452   1·0   0·06
                     Female        127           71    1·0                  107   54    0·9                         382   230   1·1   
  WBC (× 10^9^/L)    \<50          188           94    0·8   0·0009         194   95    0·8           0·0003        865   461   0·9   \<0·00005
                     ≥50           119           79    1·4                  79    56    1·5                         303   221   1·5   
  Age (years)        \<2           53            39    1·6   0·009          30    18    1·2           0·5           68    36    0·9   \<0·00005
                     2--9          208           109   0·9   (0·04 trend)   198   104   0·9           (0·2 trend)   829   450   0·9   \<0·00005 (trend)
                     10+           46            25    1·0                  45    29    1·3                         271   196   1·6   
  NCI risk           Standard      165           82    0·8   0·003          162   77    0·8           0·001         665   325   0·7   \<0·00005
                     High          142           91    1·3                  111   74    1·4                         503   357   1·5   
  Immunophenotype    non T-cell    257           142   1·0   0·4            241   127   0·9           \<0·00005     961   524   0·9   \<0·00005
                     T-cell        35            20    1·2                  25    21    2·8                         138   117   2·4   
  Time to relapse    \<18 mths     128           83    1·3   0·0003         36    31    2·8           \<0·00005     236   218   3·6   \<0·00005
                     18--30 mths   134           75    0·9   (trend)        100   68    1·3           (trend)       307   226   1·3   (trend)
                     ≥30mths       45            15    0·5                  137   52    0·6                         625   238   0·5   
  *ETV6-RUNX1*       No            80            45    1·0   0·6            73    40    1·3           0·002         324   184   1·1   0·002
                     Yes           13            6     0·8                  18    3     0·3                         64    24    0·6   
  t(9;22)            No            217           112   1·0   0·01           190   96    1·0           0·04          757   432   1·0   0·01
                     Yes           5             5     3·8                  2     2     6·2                         33    24    1·7   
  HH                 No            161           90    1·1   0·02           138   77    1·1           0·06          569   361   1·2   \<0·00005
                     Yes           56            23    0·7                  49    19    0·7                         195   83    0·6   
  *MLL* rearranged   No            218           112   1·0   0·003          187   93    1·0           0·03          768   434   1·0   0·0001
                     Yes           4             4     5·8                  6     5     3·1                         27    23    2·5   
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